Abcellera Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Abcellera Biologics
ABCL Stock  USD 3.63  0.08  2.16%   
Abcellera Biologics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Abcellera Biologics' valuation are provided below:
Gross Profit
-111.7 M
Profit Margin
(1.95)
Market Capitalization
1.1 B
Enterprise Value Revenue
22.4487
Revenue
75.1 M
There are over one hundred nineteen available fundamental signals for Abcellera Biologics, which can be analyzed over time and compared to other ratios. We recommend to validate Abcellera Biologics' prevailing fundamental drivers against the all of the trends between 2010 and 2026. The value of Market Cap is estimated to slide to about 970.5 M. The Enterprise Value is projected to slide to about 959.3 M

Abcellera Biologics Total Revenue

122.74 Million

Check Abcellera Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Abcellera Biologics' main balance sheet or income statement drivers, such as Net Interest Income of 46.5 M, Interest Income of 46.5 M or Depreciation And Amortization of 26.5 M, as well as many indicators such as Price To Sales Ratio of 12.92, Dividend Yield of 0.0 or PTB Ratio of 0.85. Abcellera financial statements analysis is a perfect complement when working with Abcellera Biologics Valuation or Volatility modules.
  
Build AI portfolio with Abcellera Stock
Check out the analysis of Abcellera Biologics Correlation against competitors.
For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.

Abcellera Biologics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.1 B1.4 B553.1 M
Slightly volatile
Short and Long Term Debt Total150.4 M143.2 M35.5 M
Slightly volatile
Other Current Liabilities18.8 M19.7 M18.5 M
Slightly volatile
Total Current Liabilities84.8 M64.3 M44.3 M
Slightly volatile
Total Stockholder Equity888.4 M1.1 B437.8 M
Slightly volatile
Other Liabilities69.6 M129.5 M44.8 M
Slightly volatile
Net Tangible Assets1.3 B1.2 B423.5 M
Slightly volatile
Property Plant And Equipment Net449.4 M428 M112.8 M
Slightly volatile
Current Deferred Revenue13.2 M13.5 M7.5 M
Slightly volatile
Accounts Payable17.2 M25.2 M9.1 M
Slightly volatile
Cash263.9 M155 M133.3 M
Slightly volatile
Non Current Assets Total408 M628.7 M201.5 M
Slightly volatile
Long Term Debt1.6 M2.5 M1.5 M
Slightly volatile
Cash And Short Term Investments573.1 M560.3 M283.8 M
Slightly volatile
Net Receivables99.9 M153.4 M49.3 M
Slightly volatile
Common Stock Total Equity479 M844.5 M294.7 M
Slightly volatile
Common Stock Shares Outstanding298 M298.7 M216.1 M
Slightly volatile
Liabilities And Stockholders Equity1.1 B1.4 B553.1 M
Slightly volatile
Non Current Liabilities Total142.7 M151.3 M71.1 M
Slightly volatile
Inventory7.7 M7.3 M1.6 M
Slightly volatile
Other Current Assets7.8 M8.2 M16.2 M
Slightly volatile
Other Stockholder Equity391.4 M372.7 M69.6 M
Slightly volatile
Total Liabilities227.5 M215.6 M115.4 M
Slightly volatile
Net Invested Capital835.1 M1.2 B436.7 M
Slightly volatile
Property Plant And Equipment Gross459 M437.2 M119.7 M
Slightly volatile
Short and Long Term Debt162.4 K171 K1.6 M
Slightly volatile
Total Current Assets707.9 M728.2 M351.6 M
Slightly volatile
Capital Stock585 M893.7 M311.9 M
Slightly volatile
Non Current Liabilities Other1.3 M1.3 M9.4 M
Pretty Stable
Net Working Capital607.7 M776 M313 M
Slightly volatile
Short Term Debt4.4 M5.8 M3.3 M
Slightly volatile
Common Stock620.1 M802.3 M304.2 M
Slightly volatile
Property Plant Equipment262.3 M249.8 M79.9 M
Slightly volatile
Non Currrent Assets Other48.9 M51.9 M22.4 M
Slightly volatile
Other Assets102 M97.1 M30.3 M
Slightly volatile
Good Will49.6 M55 M37.8 M
Slightly volatile
Short Term Investments379 M405.3 M539 M
Slightly volatile
Long Term Investments63.9 M94.6 M37.7 M
Slightly volatile
Intangible Assets36.5 M38.4 M104.9 M
Slightly volatile
Retained Earnings Total Equity381.6 M490.1 M315.4 M
Slightly volatile
Capital Surpluse60.2 M85.2 M46.6 M
Slightly volatile
Deferred Long Term Liabilities28.2 M29.9 M35.7 M
Slightly volatile

Abcellera Biologics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income46.5 M44.2 M11.3 M
Slightly volatile
Depreciation And Amortization26.5 M22.2 M13.3 M
Slightly volatile
Interest Expense2.5 M4.7 M1.7 M
Slightly volatile
Selling General Administrative87.8 M83.6 M23.4 M
Slightly volatile
Selling And Marketing Expenses15.4 M14.7 M4.8 M
Slightly volatile
Total Revenue122.7 M75.1 M63.9 M
Slightly volatile
Gross Profit109.9 M75.1 M57.6 M
Slightly volatile
Other Operating Expenses178.3 M292.2 M91.3 M
Slightly volatile
Research Development102.4 M186.8 M52.6 M
Slightly volatile
Cost Of Revenue117.1 M111.5 M32.8 M
Slightly volatile
Total Operating Expenses165.4 M292.2 M85 M
Slightly volatile
Reconciled Depreciation117.1 M111.5 M24.8 M
Slightly volatile
Total Other Income Expense Net33.9 M39.5 M17 M
Slightly volatile
Non Recurring61.6 M76.4 M52 M
Slightly volatile
Non Operating Income Net Other20.5 M26 M17.1 M
Slightly volatile

Abcellera Biologics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation38.2 M55.8 M18.9 M
Slightly volatile
Depreciation28.7 M22.2 M14.4 M
Slightly volatile
Capital Expenditures48.6 M42.8 M26.2 M
Slightly volatile
End Period Cash Flow278.8 M155.2 M140.6 M
Slightly volatile
Change To Netincome67.5 M64.3 M20.7 M
Slightly volatile
Dividends Paid11.3 K12.7 K13.9 K
Slightly volatile
Cash Flows Other Operating117.5 M176 M87.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio12.9213.5978607
Slightly volatile
PTB Ratio0.850.8951480
Slightly volatile
Days Sales Outstanding783745260
Slightly volatile
Book Value Per Share2.263.8211.5024
Slightly volatile
Stock Based Compensation To Revenue0.510.74260.3651
Slightly volatile
Capex To Depreciation2.961.92924.1628
Slightly volatile
PB Ratio0.850.8951480
Slightly volatile
EV To Sales12.7713.4408606
Slightly volatile
Inventory Turnover23.9739.0325.4338
Slightly volatile
Days Of Inventory On Hand14.959.6815.9741
Slightly volatile
Payables Turnover3.04.033.7829
Pretty Stable
Sales General And Administrative To Revenue2.382.270.6754
Slightly volatile
Research And Ddevelopement To Revenue1.52.48681.2768
Slightly volatile
Capex To Revenue0.660.56930.7122
Slightly volatile
Cash Per Share1.471.87580.9829
Slightly volatile
Days Payables Outstanding11093.6897.0812
Pretty Stable
Intangibles To Total Assets0.120.06350.1313
Slightly volatile
Current Ratio5.6611.32434.7742
Slightly volatile
Tangible Book Value Per Share1.963.53251.3045
Slightly volatile
Receivables Turnover0.470.48984.7016
Slightly volatile
Shareholders Equity Per Share2.263.8211.5024
Slightly volatile
Debt To Equity0.190.12550.2294
Slightly volatile
Capex Per Share0.130.14320.0979
Slightly volatile
Average Receivables1.4 M1.6 M1.7 M
Slightly volatile
Revenue Per Share0.240.25150.3079
Slightly volatile
Interest Debt Per Share0.50.47950.1316
Slightly volatile
Debt To Assets0.10.10550.1254
Slightly volatile
Graham Number3.966.623.0085
Slightly volatile
Operating Cycle783745262
Slightly volatile
Price Book Value Ratio0.850.8951480
Slightly volatile
Days Of Payables Outstanding11093.6897.0812
Pretty Stable
Effective Tax Rate0.250.17560.2424
Pretty Stable
Company Equity Multiplier1.611.18891.6516
Slightly volatile
Long Term Debt To Capitalization0.00290.0030.0466
Slightly volatile
Total Debt To Capitalization0.130.11150.1724
Slightly volatile
Debt Equity Ratio0.190.12550.2294
Slightly volatile
Quick Ratio5.6511.22584.7637
Slightly volatile
Net Income Per E B T0.620.82440.75
Very volatile
Cash Ratio2.92.41052.176
Slightly volatile
Days Of Inventory Outstanding14.959.6815.9741
Slightly volatile
Days Of Sales Outstanding783745260
Slightly volatile
Price To Book Ratio0.850.8951480
Slightly volatile
Fixed Asset Turnover0.170.17551.9466
Very volatile
Debt Ratio0.10.10550.1254
Slightly volatile
Price Sales Ratio12.9213.5978607
Slightly volatile
Asset Turnover0.05260.05540.3046
Slightly volatile
Gross Profit Margin0.970.990.891
Slightly volatile
Price Fair Value0.850.8951480
Slightly volatile

Abcellera Biologics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap970.5 M1 B7.6 B
Slightly volatile
Enterprise Value959.3 M1 B7.2 B
Slightly volatile

Abcellera Fundamental Market Drivers

Forward Price Earnings27.4725
Cash And Short Term Investments560.3 M

Abcellera Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Abcellera Biologics Financial Statements

Abcellera Biologics investors utilize fundamental indicators, such as revenue or net income, to predict how Abcellera Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue13.5 M13.2 M
Total Revenue75.1 M122.7 M
Cost Of Revenue111.5 M117.1 M
Stock Based Compensation To Revenue 0.74  0.51 
Sales General And Administrative To Revenue 2.27  2.38 
Research And Ddevelopement To Revenue 2.49  1.50 
Capex To Revenue 0.57  0.66 
Revenue Per Share 0.25  0.24 
Ebit Per Revenue(2.89)(3.03)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Abcellera Biologics is a strong investment it is important to analyze Abcellera Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Abcellera Biologics' future performance. For an informed investment choice regarding Abcellera Stock, refer to the following important reports:
How To Invest In Abcellera
Details
Is Abcellera Stock a good investment?
Details
What is Abcellera Biologics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Abcellera Biologics Correlation against competitors.
For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.
You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Abcellera Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
0.459
Earnings Share
(0.57)
Revenue Per Share
0.252
Quarterly Revenue Growth
7.882
Return On Assets
(0.1)
Understanding Abcellera Biologics requires distinguishing between market price and book value, where the latter reflects Abcellera's accounting equity. The concept of intrinsic value - what Abcellera Biologics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Abcellera Biologics' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that Abcellera Biologics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Abcellera Biologics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Abcellera Biologics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY